• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

保乳手术、乳腺切除术和单纯乳房切除术治疗导管原位癌患者的局部区域复发风险比较:一项单中心研究。

Comparison of locoregional recurrence risk among nipple-sparing mastectomy, skin-sparing mastectomy, and simple mastectomy in patients with ductal carcinoma in situ: a single-center study.

机构信息

Breast Center, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, Japan.

Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.

出版信息

Breast Cancer. 2024 Nov;31(6):1010-1017. doi: 10.1007/s12282-024-01613-2. Epub 2024 Jul 17.

DOI:10.1007/s12282-024-01613-2
PMID:39017823
Abstract

BACKGROUND

In invasive breast cancer, there are no differences among the mid- and long-term oncological safety results of nipple-sparing mastectomy (NSM), skin-sparing mastectomy (SSM), and simple mastectomy (SM). There are several reports comparing NSM and SSM with SM in the context of ductal carcinoma in situ (DCIS); however, the eligibility criteria vary among institutions, and there are no reports that compare all three surgical methods simultaneously within the same institution. This study aimed to compare the local recurrence and survival rates of the three techniques (NSM, SSM, and SM) in Japanese patients undergoing mastectomy for DCIS.

METHODS

Patients undergoing NSM, SSM, or SM at our institution between 2006 and 2015 were identified, and their outcomes were analyzed.

RESULTS

The mean follow-up period was 80.4 months (standard deviation [SD]: 37.1 months). NSM was performed in 152 cases, SSM in 49, and SM in 44. Five of 245 patients developed local recurrences. Four of these patients had invasive cancer. The primary endpoints of 5-year cumulative local recurrence were 2.4% (95% confidence interval [CI]: 0.0-5.0) for NSM, 2.2% (95% CI: 0.0-6.3) for SSM, and 0% (95% CI: 0.0-0.0) for SM. There were no significant differences among the 5-year local recurrence rates.

CONCLUSIONS

In this single-center, retrospective study, the oncological safety of SSM and NSM for DCIS was comparable to that of conventional SM.

摘要

背景

在浸润性乳腺癌中,保乳头乳晕复合体的乳房切除术(NSM)、保留皮肤的乳房切除术(SSM)和单纯乳房切除术(SM)的中、长期肿瘤安全性结果并无差异。有几篇报道比较了 NSM 和 SSM 与 SM 在导管原位癌(DCIS)中的情况;然而,各机构的纳入标准不同,而且没有在同一机构内同时比较所有三种手术方法的报道。本研究旨在比较三种手术方法(NSM、SSM 和 SM)在日本 DCIS 患者乳房切除术中的局部复发率和生存率。

方法

我们机构在 2006 年至 2015 年间对行 NSM、SSM 或 SM 的患者进行了识别,并对其结局进行了分析。

结果

平均随访时间为 80.4 个月(标准差 [SD]:37.1 个月)。行 NSM 者 245 例,SSM 者 49 例,SM 者 44 例。245 例患者中有 5 例发生局部复发。其中 4 例为浸润性癌。NSM、SSM 和 SM 的 5 年累积局部复发率的主要终点分别为 2.4%(95%可信区间 [CI]:0.0-5.0)、2.2%(95% CI:0.0-6.3)和 0%(95% CI:0.0-0.0)。5 年局部复发率无显著差异。

结论

在这项单中心回顾性研究中,SSM 和 NSM 治疗 DCIS 的肿瘤安全性与传统 SM 相当。

相似文献

1
Comparison of locoregional recurrence risk among nipple-sparing mastectomy, skin-sparing mastectomy, and simple mastectomy in patients with ductal carcinoma in situ: a single-center study.保乳手术、乳腺切除术和单纯乳房切除术治疗导管原位癌患者的局部区域复发风险比较:一项单中心研究。
Breast Cancer. 2024 Nov;31(6):1010-1017. doi: 10.1007/s12282-024-01613-2. Epub 2024 Jul 17.
2
Nipple-sparing mastectomy as treatment for patients with ductal carcinoma in situ: A 10-year follow-up study.保留乳头的乳房切除术治疗导管原位癌患者:一项10年随访研究。
Breast J. 2018 May;24(3):298-303. doi: 10.1111/tbj.12947. Epub 2017 Nov 15.
3
Nipple-sparing mastectomy and immediate reconstruction in ductal carcinoma in situ: a critical assessment with 41 patients.保乳根治术及原位导管癌即刻乳房重建:41例患者的关键评估
Aesthetic Plast Surg. 2014 Apr;38(2):338-43. doi: 10.1007/s00266-013-0236-8. Epub 2014 Jan 30.
4
Recurrence Outcomes After Nipple-Sparing Mastectomy and Immediate Breast Reconstruction in Patients with Pure Ductal Carcinoma In Situ.保乳术后及即刻乳房重建治疗单纯导管原位癌患者的复发结局。
Ann Surg Oncol. 2020 May;27(5):1627-1635. doi: 10.1245/s10434-019-08184-z. Epub 2020 Jan 7.
5
Nipple- and areola-sparing mastectomy for the treatment of breast cancer.保留乳头乳晕的乳房切除术治疗乳腺癌。
Cochrane Database Syst Rev. 2016 Nov 29;11(11):CD008932. doi: 10.1002/14651858.CD008932.pub3.
6
Long-Term Oncologic Safety of Nipple-Sparing Mastectomy With Immediate Reconstruction.保留乳头的乳房切除术即刻再造的长期肿瘤安全性。
Clin Breast Cancer. 2021 Aug;21(4):352-359. doi: 10.1016/j.clbc.2021.01.002. Epub 2021 Jan 6.
7
Long-term outcomes of patients with breast cancer after nipple-sparing mastectomy/skin-sparing mastectomy followed by immediate transverse rectus abdominis musculocutaneous flap reconstruction: Comparison with conventional mastectomy in a single center study.保留乳头乳房切除术/保留皮肤乳房切除术后即刻行腹直肌肌皮瓣重建的乳腺癌患者的长期预后:单中心研究中与传统乳房切除术的比较
Medicine (Baltimore). 2018 May;97(18):e0680. doi: 10.1097/MD.0000000000010680.
8
Oncologic outcomes after nipple-sparing mastectomy: A single-institution experience.保乳术后的肿瘤学结果:单机构经验。
J Surg Oncol. 2016 Jan;113(1):8-11. doi: 10.1002/jso.24097. Epub 2015 Dec 2.
9
Positive Nipple Margins in Nipple-Sparing Mastectomy: Management of Nipples Containing Cancer or Atypia.保乳手术中乳头切缘阳性:含癌或异型增生乳头的处理
Ann Surg Oncol. 2024 Aug;31(8):5148-5156. doi: 10.1245/s10434-024-15362-1. Epub 2024 May 1.
10
Nipple sparing mastectomy for breast cancer is associated with high patient satisfaction and safe oncological outcomes.乳腺癌保乳乳房切除术能带来较高的患者满意度和安全的肿瘤学预后。
J Gynecol Obstet Hum Reprod. 2017 Oct;46(8):637-642. doi: 10.1016/j.jogoh.2017.07.003. Epub 2017 Jul 8.

引用本文的文献

1
Postmastectomy Breast Reconstruction in Patients with Non-Metastatic Breast Cancer: A Systematic Review.非转移性乳腺癌患者乳房切除术后乳房重建:一项系统评价
Curr Oncol. 2025 Apr 16;32(4):231. doi: 10.3390/curroncol32040231.
2
Disease recurrence in patients undergoing mastectomy for ductal carcinoma in situ.接受原位导管癌乳房切除术患者的疾病复发情况。
Breast Cancer Res Treat. 2025 Feb;209(3):675-679. doi: 10.1007/s10549-024-07530-4. Epub 2024 Nov 1.

本文引用的文献

1
Characteristics of female breast cancer in japan: annual report of the National Clinical Database in 2018.日本女性乳腺癌特征:2018 年全国临床数据库年度报告。
Breast Cancer. 2023 Mar;30(2):157-166. doi: 10.1007/s12282-022-01423-4. Epub 2022 Dec 22.
2
Oncological outcomes after simple and skin-sparing mastectomy of ductal carcinoma in situ: A register-based cohort study of 576 Norwegian women.导管原位癌单纯乳房切除术和保留皮肤乳房切除术后的肿瘤学结局:一项基于登记的对576名挪威女性的队列研究。
Eur J Surg Oncol. 2023 Mar;49(3):575-582. doi: 10.1016/j.ejso.2022.11.594. Epub 2022 Dec 1.
3
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
《NCCN 肿瘤学临床实践指南:乳腺癌》第 3.2022 版
J Natl Compr Canc Netw. 2022 Jun;20(6):691-722. doi: 10.6004/jnccn.2022.0030.
4
Nipple-sparing Mastectomy: What the Radiologist Should Know.保留乳头的乳房切除术:放射科医生应了解的内容。
Radiographics. 2022 Mar-Apr;42(2):321-339. doi: 10.1148/rg.210136. Epub 2022 Feb 18.
5
Pattern of local recurrence after mastectomy and reconstruction in breast cancer patients: a systematic review.乳腺癌患者乳房切除术后局部复发及重建模式:一项系统评价
Gland Surg. 2021 Jun;10(6):2037-2046. doi: 10.21037/gs-21-15.
6
Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy.保乳手术与乳房切除术治疗导管原位癌患者的浸润性复发模式。
Breast Cancer Res Treat. 2021 Apr;186(3):617-624. doi: 10.1007/s10549-021-06129-3. Epub 2021 Mar 6.
7
Oncologic Safety of Nipple-Sparing Mastectomy in Patients with Breast Cancer and Tumor-to-Nipple Distance ≤ 1 cm: A Matched Cohort Study.保乳手术联合乳房重建治疗肿瘤距乳头距离≤1cm 的乳腺癌患者的安全性:一项匹配队列研究
Ann Surg Oncol. 2021 Aug;28(8):4284-4291. doi: 10.1245/s10434-020-09427-0. Epub 2021 Jan 9.
8
Annual report of the Japanese Breast Cancer Registry for 2017.2017 年日本乳腺癌注册中心年度报告。
Breast Cancer. 2020 Sep;27(5):803-809. doi: 10.1007/s12282-020-01139-3. Epub 2020 Jul 24.
9
Annual report of the Japanese Breast Cancer Society registry for 2016.2016 年日本乳腺癌学会注册年度报告。
Breast Cancer. 2020 Jul;27(4):511-518. doi: 10.1007/s12282-020-01081-4. Epub 2020 May 11.
10
Recurrence Outcomes After Nipple-Sparing Mastectomy and Immediate Breast Reconstruction in Patients with Pure Ductal Carcinoma In Situ.保乳术后及即刻乳房重建治疗单纯导管原位癌患者的复发结局。
Ann Surg Oncol. 2020 May;27(5):1627-1635. doi: 10.1245/s10434-019-08184-z. Epub 2020 Jan 7.